Welcome to Industry Focus. The Podcast that dives into a different sector of the stock market each day.

I'm your host Emily Flippin. I'm Jason Moser. I'm Nick Seyple. I'm Dylan Lewis. And today

we're talking financials. Today we're talking consumer goods. Wild Card Wednesday.

And we're talking energy. And today we're talking tech.

Let's dive in.

Welcome to Industry Focus.

Today is Wednesday, September 21st.

And I'm your host, Emily Flippin. Today I am joined by Carl Thiel, who was making his first industry-focused debut as a full-time advisor on our team here at the

Fool and we're going to be talking CRISPR gene editing technology.

Carl you've been a long time fool but you're relatively new full-time fool.

So how's it going so far?

It's been going great. It's you know I I get to see how the sausage is made in a different way I suppose and the

sausage is yummy so it's good stuff. Yeah hopefully it hasn't turned off your appetite seeing behind the scenes a little bit.

Well as part of our team you've been heading up our new biotech breakthrough service.

So I thought it'd be fun to have you on today and talk CRISPR technology. I will say that A should not be

confused with CRISPR therapeutics, which is just one of a handful of companies that are looking

to capitalize on this technology.

But I will say, I am a generalist a bit in this space.

I know that you've been working in and following this space for decades.

So you have a lot more specialized knowledge here than I do.

So selfishly, I'm really excited to hear you, I guess,

give your thoughts about this entire industry.

...